Complete response with fotemustine and bevacizumab after early progression following radiotherapy and temozolomide treatment in patient with glioblastoma multiforme

发表时间：2015-11-24 浏览次数：1285次

引用：

Calvo OF, Pérez López ME, Gómez JG. Complete response with fotemustine and bevac

关键词：

作者：

Ovidio Fernández Calvo, María Eva Pérez López, Jes

作者单位：

Department of Medical Oncology, Ourense University

出版年份：

2015

期刊页数：

36-38

收录者：

其他外文数据库

摘要：

Glioblastoma multiforme is the most common type of primary central nervous system tumor and is noted for its short survival and poor response to chemotherapeutic agents. Unfortunately, the relapse rate is very high, and there is no reference drug for second-line treatment. In this study, a patient was treated with the Soffietti regimen. The induction phase was fotemustine 75 mg/m 2 at day 1 and day 8 and bevacizumab 10 mg/kg at day 1 and day 15. The maintenance phase was fotemustine 75 mg/m 2 and bevacizumab 10 mg/kg every 3 weeks for two cycles. Follow-up magnetic resonance imaging showed post-surgical changes at the left occipital level, without contrast enhancement, and toxic left leuko-encephalopathy post-treatment without mass effect and with no evidence of tumor residue. The patient then was maintained with bevacizumab monotherapy until it was withdrawn when pulmonary thromboembolism occurred. Following tumor regrowth, fotemustine was started again as maintenance therapy. The patient achieved stabilization of his disease until his death due to thromboembolic and infectious complications.

阅读全文